SHSE:600993'
s EV-to-FCF Range Over the Past 10 Years
Min: -919.14 Med: 20.66 Max: 648.13
Current: 12.93
During the past 13 years, the highest EV-to-FCF of Mayinglong Pharmaceutical Group Co was 648.13. The lowest was -919.14. And the median was 20.66.
SHSE:600993's EV-to-FCF is ranked better than 67.97% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs SHSE:600993: 12.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mayinglong Pharmaceutical Group Co (SHSE:600993) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mayinglong Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Mayinglong Pharmaceutical Group Co's share price for today is ¥23.25.
Mayinglong Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mayinglong Pharmaceutical Group Co EV-to-FCF Related Terms
Mayinglong Pharmaceutical Group Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's EV-to-FCF falls into.
Mayinglong Pharmaceutical Group Co's current Enterprise Value is ¥7,707 Mil.
Mayinglong Pharmaceutical Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥596 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a EV-to-FCF of 12.93 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. This is 37% below median its historical median of 20.66. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #180 out of 562 companies in the Drug Manufacturers industry, placing it in the top 32%.
Is Mayinglong Pharmaceutical Group Co's EV-to-FCF too high?
Mayinglong Pharmaceutical Group Co's current EV-to-FCF of 12.93 is 37% below median its 10-year median of 20.66. The Drug Manufacturers industry median EV-to-FCF is 20.96. Mayinglong Pharmaceutical Group Co's value of 12.93 is 38.3% below this industry median. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #180 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #180 out of 562 companies for EV-to-FCF. This puts Mayinglong Pharmaceutical Group Co in the upper half of its industry. The industry median EV-to-FCF is 20.96. Mayinglong Pharmaceutical Group Co's value of 12.93 is 38.3% below this benchmark. While the company's 10-year median is 20.66 vs. the industry median of 20.96, Mayinglong Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayinglong Pharmaceutical Group Co's current EV-to-FCF of 12.93 is 38.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayinglong Pharmaceutical Group Co's current EV-to-FCF is 12.93, which is 37% below median its own 10-year median of 20.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.53, compared to a current price of ¥23.25 — trading 21.3% below its estimated fair value. The current EV-to-FCF is 12.93, which is 37% below median its 10-year median of 20.66 and 38.3% below the Drug Manufacturers industry median of 20.96. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current EV-to-FCF is 12.93 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.25 is trading 21.3% below its estimated GF Value™ of ¥29.53.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
EV-to-FCF: 12.93 (37% below median its 10-year median of 20.66)
GF Value™: ¥29.53 vs. price of ¥23.25 (21.3% below fair value)
Industry Position: 38.3% below the Drug Manufacturers median (#180 of 562)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Business Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
92GF Score
Get the complete analysis for SHSE:600993
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
